(Total Views: 747)
Posted On: 09/16/2020 6:08:01 PM
Post# of 154104
I'm still struggling to come up with a valid explanation why they would title a 8/17/20 press release:
and then casually explain a month later on the CC that they just discussed EUA with the FDA and never submitted a formal application.
Back on 8/17 they could have simply wrote: "and will immediately initiate discussions for emergency use approval.". Which begs the question: Did they intend to mislead?
And with newly shaken confidence regarding what NP says in PRs and what he actually does, why shouldn't we fear the same will occur with interim CD12 data in several weeks?
The ability to cross the blood brain barrier is great news, as is their NASH trial progress and long hauler approach but the CYDY C Suite MUST be aware that investors are way beyond being satisfied with "big future" chatter and are now laser focused on some sort of FDA approval in the nearer term.
Quote:
"CytoDyn Submits its Top-line Report from its Phase 2 COVID-19 Trial to the U.S. FDA and Requests Emergency Use Approval"
and then casually explain a month later on the CC that they just discussed EUA with the FDA and never submitted a formal application.
Back on 8/17 they could have simply wrote: "and will immediately initiate discussions for emergency use approval.". Which begs the question: Did they intend to mislead?
And with newly shaken confidence regarding what NP says in PRs and what he actually does, why shouldn't we fear the same will occur with interim CD12 data in several weeks?
The ability to cross the blood brain barrier is great news, as is their NASH trial progress and long hauler approach but the CYDY C Suite MUST be aware that investors are way beyond being satisfied with "big future" chatter and are now laser focused on some sort of FDA approval in the nearer term.
(13)
(0)
